A consortium led by Causeway Sensors wins Innovate UK award to enable better, cheaper, more sustainable medicine
Causeway Sensors has developed an innovative nanosensor device, TITAN, that can measure critical product quality attributes in real-time from bioproduction lines. This data is then made available so better decisions can be made to control drug production processes.
A £422k consortium aims to demonstrate TITAN’s capabilities in so-called downstream operations to enhance process efficiency and sustainability, ultimately improving drug quality and lowering the cost of therapies. Forming this consortium, Causeway Sensors is joined by technology innovation centre, CPI and Industrial Systems and Control (ISC) to answer Innovate UK’s call for “Flexible, agile, scalable and sustainable medicines manufacturing”.
Therapeutic monoclonal antibodies (mAbs) have become a dominant product class within the biopharmaceutical market, treating various diseases, including rheumatoid arthritis and cancer. Improving the manufacture of these highly advanced therapies requires more efficient, real-time information about the production process and better automation is required.
To accomplish this, within the consortium, CPI will make available their end-to-end continuous biomanufacturing system as a testbed, integrating Causeway Sensors’ TITAN device, enabling real-time product analysis, and applying ISC’s expertise in automation and process control. This will result in a highly sophisticated system, incorporating state-of-the- art hardware and software, focusing on Cation Exchange and Anion Exchange, two crucial components in biotherapeutic purification, to maximise the yield and purity of the final biotherapeutic product.
Sustainability in bioprocessing is a critical facet of the industry. This project aims to reduce water and energy consumption, minimise waste generation, and establish intensified purification processes that are cheaper, faster and more environmentally conscious.
Antony Murphy, CEO of Causeway Sensors, commented on the project:
“We’ve already proven that our TITAN biosensor gives high-quality data, and this project puts TITAN in a pivotal position, where it can provide real-time monitoring of these critical outputs while our partners’ automation and process control expertise greatly enhances the value of this data, pushing the boundaries of continuous biomanufacturing.”
Please click here to download our press release on this story. Any media requests can be directed to dkane@causewaysensors.com.